Investor Overview

Corporate Profile

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule, oligomer antagonists for age-related degenerative disorders of the central nervous system. We are currently investigating our lead candidate zervimesine (also known as CT1812) in clinical programs in Alzheimer’s disease and dementia with Lewy bodies (DLB).

Read a letter from our CEO
View Stock Information
Corporate
Corporate Presentation (PDF)

Press Releases

February 20, 2025
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
January 30, 2025
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
January 8, 2025
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
View All Press Releases

Events

January 29, 2025 - January 31, 2025
International Lewy Body Dementia Conference (ILBDC) 2025
View Presentation
January 12, 2025
Sachs 8th Annual Neuroscience Innovation Forum
January 11, 2025
Longwood Healthcare Leaders Stanford Summit
View All Events

SEC Filings

View All SEC Filings

Investor Relations Contact

Cognition Therapeutics
info@cogrx.com

Mikey Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Email Alerts

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.brightfocus.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.preventblindness.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to https://lewybodyresourcecenter.org/

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.lbda.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.alz.org